Anti-Leukemia Activity of MS-275 Histone Deacetylase Inhibitor Implicates 4-1BBL/4-1BB Immunomodulatory Functions
Bérengère Vire, Stéphane de Walque, Audrey Restouin et al. · 2009
Read Anti-Leukemia Activity of MS-275 Histone Deacetylase Inhibitor Implicates 4-1BBL/4-1BB Immunomodulatory Functions by Bérengère Vire, Stéphane de Walque, Audrey Restouin et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0007085.txt.
Description
Bérengère Vire, Stéphane de Walque, Audrey Restouin, and colleagues tested a leukemia drug in PLOS ONE in 2009. Histone deacetylase inhibitors had shown promise against blood cancers in trials. One such drug, MS-275, kills leukemic blasts by triggering apoptosis. The killing was thought to run through death receptor pathways.
The team linked MS-275's activity to an immune pair, 4-1BBL and its receptor 4-1BB. That pair usually helps coordinate immune cells. If a cancer drug also wakes immune signaling, its benefits may be double. The finding suggests combining such drugs with immune therapies for leukemia.
Catalog record
| CREATOR | Bérengère Vire, Stéphane de Walque, Audrey Restouin et al. |
|---|---|
| YEAR | 2009 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 58 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0007085